drugset / Trial / NCT01211197

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

NCT01211197

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the current study is to determine the relative bioavailability of a BI 10773 / metformin fixed dose combination tablet compared to single tablets of BI 10773 and metformin when administered together and to assess the effect of food on the bioavailability the fixed dose combination tablet

Timeline

Start
2010-10
Primary completion
2010-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 12.5 mg
Subject Metformin Small molecule 1000 mg